Entact Bio is a protein function drug developer and is currently in the preclinical stage of developing drugs to improve protein function. Recently, Entact Bio announced the completion of $81 million in Series A financing to advance the company’s proprietary Encompass 
platform. The round was co-led by Qiming Venture Partners USA and venBio Partners.
This article is transferred from: https://www.itjuzi.com/investevent/13708464
This site is only for collection, and the copyright belongs to the original author.